Hetrombopag to prevent low platelets from ADC therapy in breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer confirmed by a biopsy or cell test.
- You are about to start ADC chemotherapy (Cohort 1) or have had a low platelet count (below 75) from ADC chemo and plan to continue the same chemo (Cohort 2).
- Your kidneys and liver work well enough based on standard blood tests.
- You have not had a blood clot, serious bleeding, or certain heart problems in the last 6 months.
- You agree to use birth control during and for 6 months after the study if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if Hetrombopag can prevent low blood platelets caused by gemcitabine and cisplatin chemotherapy for nasopharyngeal carcinoma. It may help patients who had low platelets in a previous chemo cycle.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
This study tests a medication called eltrombopag to help prevent dangerously low platelet counts (blood cells that help clotting) in breast cancer patients receiving chemotherapy. Low platelets can cause bleeding problems, and this drug may help keep your counts safer during treatment.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
Hear when a new CTIT-Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.